1. Home
  2. MLYS vs USNA Comparison

MLYS vs USNA Comparison

Compare MLYS & USNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MLYS
  • USNA
  • Stock Information
  • Founded
  • MLYS 2019
  • USNA 1992
  • Country
  • MLYS United States
  • USNA United States
  • Employees
  • MLYS N/A
  • USNA N/A
  • Industry
  • MLYS Biotechnology: Pharmaceutical Preparations
  • USNA Medicinal Chemicals and Botanical Products
  • Sector
  • MLYS Health Care
  • USNA Health Care
  • Exchange
  • MLYS Nasdaq
  • USNA Nasdaq
  • Market Cap
  • MLYS 526.1M
  • USNA 648.2M
  • IPO Year
  • MLYS 2023
  • USNA 1996
  • Fundamental
  • Price
  • MLYS $10.46
  • USNA $31.32
  • Analyst Decision
  • MLYS Strong Buy
  • USNA Hold
  • Analyst Count
  • MLYS 2
  • USNA 1
  • Target Price
  • MLYS $30.00
  • USNA $38.00
  • AVG Volume (30 Days)
  • MLYS 263.5K
  • USNA 123.0K
  • Earning Date
  • MLYS 03-20-2025
  • USNA 02-25-2025
  • Dividend Yield
  • MLYS N/A
  • USNA N/A
  • EPS Growth
  • MLYS N/A
  • USNA N/A
  • EPS
  • MLYS N/A
  • USNA 2.83
  • Revenue
  • MLYS N/A
  • USNA $861,973,000.00
  • Revenue This Year
  • MLYS N/A
  • USNA N/A
  • Revenue Next Year
  • MLYS N/A
  • USNA $11.73
  • P/E Ratio
  • MLYS N/A
  • USNA $11.08
  • Revenue Growth
  • MLYS N/A
  • USNA N/A
  • 52 Week Low
  • MLYS $8.58
  • USNA $30.92
  • 52 Week High
  • MLYS $16.91
  • USNA $52.75
  • Technical
  • Relative Strength Index (RSI)
  • MLYS 51.57
  • USNA 31.12
  • Support Level
  • MLYS $9.81
  • USNA $30.92
  • Resistance Level
  • MLYS $10.79
  • USNA $36.25
  • Average True Range (ATR)
  • MLYS 0.62
  • USNA 0.99
  • MACD
  • MLYS 0.15
  • USNA -0.20
  • Stochastic Oscillator
  • MLYS 100.00
  • USNA 14.63

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking three or more antihypertensive medications typically including a diuretic.

About USNA USANA Health Sciences Inc.

Usana Health Sciences Inc is a U.S.-based company that is principally engaged in developing, manufacturing, and selling science-based nutritional and personal-care products. The company operates through direct selling. It owns a number of product lines, such as Essentials, which contains core vitamin and mineral supplements; Optimizers, which includes targeted supplements for individuals' health and nutritional needs; Foods, which consists of low-glycemic meal replacement shakes, snack bars, and other related products; and Sense Beautiful Science, which contains personal-care products related to skin and hair. The company conducts business worldwide, including Asia-Pacific, the Americas, and Europe.

Share on Social Networks: